NEW YORK, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liberty Health Sciences Inc. (“Liberty” or the “Company”) (OTCMKT: LHSIF). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/lhsif.

The investigation concerns whether Liberty and certain of its officers and/or directors have violated federal securities laws.

In September 2018, Aphria Inc. revealed that it had sold off its stake in Liberty Health. Then on December 3, 2018, Quintessential Capital Management and Hindenburg Research published a report claiming that Aphria was part of a scheme involving the acquisition of shell companies at artificially inflated prices. Following this news, Liberty’s stock dropped $0.36 per share or nearly 34% over the next two trading days to close at $0.70 on December 4, 2018.

If you are aware of any facts relating to this investigation, or purchased Liberty shares, you can assist this investigation by visiting the firm’s site: bgandg.com/lhsif. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com